Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck
dc.contributor.author | Doroshow, James | en_US |
dc.contributor.author | Dallaire, Brian | en_US |
dc.contributor.author | Carlson, Randall | en_US |
dc.contributor.author | Gyves, John W. | en_US |
dc.contributor.author | Grillo-Lopez, Antonio | en_US |
dc.contributor.author | Robert, Francisco | en_US |
dc.contributor.author | Adams, David | en_US |
dc.contributor.author | Velez-Garcia, Enrique | en_US |
dc.contributor.author | Cripps, Christine | en_US |
dc.contributor.author | Urba, Susan G. | en_US |
dc.date.accessioned | 2006-09-11T18:22:57Z | |
dc.date.available | 2006-09-11T18:22:57Z | |
dc.date.issued | 1992-03 | en_US |
dc.identifier.citation | Urba, Susan; Doroshow, James; Cripps, Christine; Robert, Francisco; Velez-Garcia, Enrique; Dallaire, Brian; Adams, David; Carlson, Randall; Grillo-Lopez, Antonio; Gyves, John; (1992). "Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck." Cancer Chemotherapy and Pharmacology 31(2): 167-169. <http://hdl.handle.net/2027.42/46923> | en_US |
dc.identifier.issn | 0344-5704 | en_US |
dc.identifier.issn | 1432-0843 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/46923 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=1451236&dopt=citation | en_US |
dc.description.abstract | A total of 19 patients with advanced squamous-cell carcinoma of the head and neck who had not previously been exposed to chemotherapy were treated with brequinar sodium as first-line chemotherapy. Brequinar was given intravenously at a median weekly dose of 1,200 mg/m 2 . The toxicity was moderate, with 7 patients (37%) experiencing grade 3 or 4 toxicity. In all, 16 patients who were evaluable for efficacy showed no objective response. We conclude that brequinar given at this dose and on this schedule has no significant activity in advanced squamous-cell carcinoma of the head and neck. | en_US |
dc.format.extent | 266540 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag | en_US |
dc.subject.other | Oncology | en_US |
dc.subject.other | Cancer Research | en_US |
dc.subject.other | Biomedicine | en_US |
dc.subject.other | Pharmacology/Toxicology | en_US |
dc.title | Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Radiology | en_US |
dc.subject.hlbsecondlevel | Chemistry | en_US |
dc.subject.hlbsecondlevel | Chemical Engineering | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Engineering | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor, MI, USA; Department of Oncology, The DuPont Merck Pharmaceutical Company, P. O. Box 80026, P26/1160, 19880-0026, Wilmington, DE, USA | en_US |
dc.contributor.affiliationother | San Juan Veterans' Hospital, San Juan, PR, USA; University of Alabama at Birmingham, Birmingham, AL, USA | en_US |
dc.contributor.affiliationother | Department of Oncology, The DuPont Merck Pharmaceutical Company, P. O. Box 80026, P26/1160, 19880-0026, Wilmington, DE, USA | en_US |
dc.contributor.affiliationother | City of Hope National Medical Center, Duarte, CA, USA | en_US |
dc.contributor.affiliationother | Ottawa Regional Cancer Center, Ottawa, Ontario, Canada | en_US |
dc.contributor.affiliationother | University of Puerto Rico School of Medicine, San Juan, Puerto Rico, USA | en_US |
dc.contributor.affiliationother | Department of Oncology, The DuPont Merck Pharmaceutical Company, P. O. Box 80026, P26/1160, 19880-0026, Wilmington, DE, USA | en_US |
dc.contributor.affiliationother | Department of Oncology, The DuPont Merck Pharmaceutical Company, P. O. Box 80026, P26/1160, 19880-0026, Wilmington, DE, USA | en_US |
dc.contributor.affiliationother | Department of Oncology, The DuPont Merck Pharmaceutical Company, P. O. Box 80026, P26/1160, 19880-0026, Wilmington, DE, USA | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 1451236 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/46923/1/280_2004_Article_BF00685106.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF00685106 | en_US |
dc.identifier.source | Cancer Chemotherapy and Pharmacology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.